Daily Digest

The Valve Wire

Thursday, May 7, 2026

Executive Summary

Today's digest arrives from the AATS Annual Meeting in full swing, where a landmark consensus document on atrial functional mitral regurgitation (AFMR) was released — the first comprehensive surgical-society framework for this increasingly recognized disease entity. Meanwhile, a major JAMA Cardiology study reveals a troubling and widening sex gap in TAVR access, with women comprising a shrinking share of procedures despite better long-term survival. And a pointed editorial in the Annals of Thoracic Surgery from Badhwar, Mehaffey, and Wolfe sounds a fresh alarm on TAVR expansion into younger patients — a warning that deserves careful attention as the field debates age thresholds for transcatheter vs. surgical intervention.

For the clinical audience: this is a day to step back from device enthusiasm and confront the harder questions. The AATS AFMR consensus document (JTCVS) provides 18 graded recommendations that formally align with the ESC 2025 recognition of atrial secondary MR as a distinct entity — but goes further with actionable guidance on rhythm management, surgical technique, and transcatheter candidacy. The JAMA Cardiology analysis of 314,123 Medicare TAVI patients is the largest sex-stratified TAVR outcomes study to date, and the finding that women face more complications yet live longer demands mechanistic explanation and procedural adaptation. The Badhwar/Mehaffey editorial, while brief, crystallizes the surgical community's central objection to expanding TAVR below age 70: convenience now may mean complexity later, especially when lifetime valve management is considered. Add in new data on CT-derived frailty markers for M-TEER risk stratification, real-world surgical repair rates from the MITRACURE registry, and a preprint dissecting flow-gradient phenotypes after TAVI, and you have a day that touches every major debate in structural heart disease.

Today's Key Findings

[NOTABLE] JAMA Cardiology: In 314,123 Medicare TAVI patients (2013–2022), women constituted a declining share of procedures (47.6% → 43.6%), experienced higher periprocedural mortality (2.5% vs 2.2%), more vascular complications and bleeding, but had modestly better long-term survival (AHR 0.92). This paradox demands action on sex-specific device sizing, access strategies, and referral patterns.
[NOTABLE] AATS Consensus Document on AFMR (JTCVS): An international panel achieved consensus on 18 graded statements covering diagnosis, medical/rhythm therapy, surgical intervention, TEER, and postoperative management of atrial functional MR — the most comprehensive framework to date for this entity.
[NOTABLE] Annals of Thoracic Surgery Editorial — "Convenience Now, Complexity Later": Badhwar, Mehaffey, and Wolfe argue directly against TAVR expansion into younger patients, emphasizing the unresolved burden of lifetime management, reintervention complexity, and the risk of indication creep.
MITRACURE Registry (JTCVS): In 2,135 patients with degenerative MR across 40 centers, MV repair rate was 80% but only 4% received early intervention. In-hospital mortality was 2.3% overall (1.4% repair vs 6.2% replacement). High-volume centers achieved 84% repair rates vs 68% at low-volume centers.
Circ: Cardiovascular Imaging: CT-derived fatty muscle fraction independently predicted mortality after M-TEER, with 30.3% one-year mortality in the highest tertile vs 7.7% in the lowest — a potentially practice-changing frailty biomarker.

Aortic Valve (TAVR/TAVI)

Sex Disparities in TAVR: Largest US Study to Date (JAMA Cardiology)

[NOTABLE] Nicolas, Gelijns, Leon, Mehran and colleagues present a nationwide analysis of 314,123 Medicare fee-for-service TAVI patients from 2013–2022. The findings are striking and dissonant: women made up a declining share of TAVI procedures (from 47.6% to 43.6%, P<0.001), had higher periprocedural mortality (AOR 1.20), more vascular complications (AOR 1.65), and more bleeding (AOR 1.67) — yet demonstrated better adjusted long-term survival (AHR 0.92). Men had higher rates of permanent pacemaker implantation (20.0% vs 16.9%).

Editorial perspective: The declining female share of TAVI is concerning and likely reflects referral bias rather than disease prevalence — aortic stenosis is at least as common in women. The higher complication rates in women likely relate to smaller vascular anatomy and annular dimensions, underscoring the need for sex-specific device iterations, vascular closure optimization, and potentially different procedural thresholds. The survival advantage in women despite more complications mirrors broader cardiovascular epidemiology and may reflect the older age and greater comorbidity burden of men selected for TAVI. This is a JAMA Cardiology paper — it warrants Heart Team attention and likely guideline discussion.

"Convenience Now, Complexity Later" — Surgical Pushback on Young TAVR (Annals of Thoracic Surgery)

[NOTABLE] Wolfe, Mehaffey, and Badhwar publish a direct editorial challenge to the trend of expanding TAVR into younger, lower-risk patients. While the abstract is unavailable, the title and authorship signal a continuation of the argument these authors have made forcefully: that the ESC 2025 lowering of the TAVI-preferred threshold to age 70 and favorable meta-analyses have gotten ahead of the evidence on long-term durability, lifetime valve management, and reintervention complexity.

Editorial perspective: This editorial lands during the AATS Annual Meeting — a surgical forum — so context matters. But the concerns are legitimate and insufficiently addressed by transcatheter advocates. The 2025 ESC guidelines themselves acknowledge that patients under 70 are poorly represented in RCTs, and that THV explantation carries 12–17% mortality. The recent meta-analysis showing a TAVR mortality advantage at 5 years (HR 0.80) relied on trials with variable risk stratification, and as Kaul has noted, when intermediate-risk trials are excluded, the mortality difference disappears. The ACC/AHA 2020 guidelines remain more conservative, preferring SAVR below age 65. Until we have robust 10–15 year durability data and proven reintervention pathways, this editorial serves as an essential counterweight to industry enthusiasm.

Paradoxical Low-Flow Low-Gradient AS: State-of-the-Art Review (American Journal of Cardiology)

Armonis et al. provide a comprehensive review of paradoxical low-flow, low-gradient AS — the phenotype of severe stenosis with preserved LVEF but reduced stroke volume that confounds grading. The review synthesizes the diagnostic algorithm: integrative Doppler echo, low-dose dobutamine stress, and CT calcium scoring (thresholds: >2000 AU men, >1200 AU women per current guidelines). While AVR improves survival in confirmed true-severe disease, phenotype-specific comparative data between TAVI and SAVR remain limited.

Clinical note: The preprint from Ravn et al. (below) complements this review nicely — showing that pLFLG patients have attenuated functional recovery after TAVI compared to other flow-gradient phenotypes. This underscores that confirming true-severe disease is critical before committing patients to intervention.

Dexmedetomidine and Pacemaker Risk After TAVR (J Cardiothorac Vasc Anesth)

Fried et al. report a single-center retrospective study of 2,022 TAVR procedures under monitored anesthesia care, finding that intraoperative dexmedetomidine was not associated with increased permanent pacemaker implantation at any dose level. The overall PPM rate was approximately 9–10%. Confirmed risk factors for PPM included male sex (OR 1.89), pre-existing conduction abnormalities (OR 2.64), self-expanding valves (OR 2.65), and larger valve sizes. This is reassuring for anesthesia teams using DEX, though the single-center retrospective design limits generalizability.

Frailty After AVR: No Clear Improvement (Heart, Lung & Circulation)

A systematic review and meta-analysis of 1,798 patients across 9 studies found no overall change in frailty after either TAVI or SAVR. However, a sensitivity analysis revealed that lower-risk TAVI patients (STS-PROM ≤5%) did show frailty improvements, while higher-risk patients did not — regardless of whether they received TAVI or SAVR. The high heterogeneity across studies limits conclusions, but the message is important: aortic valve intervention is not a frailty cure, especially in the sickest patients. This argues against the assumption that TAVI will "reset" frailty in patients selected primarily because they are too frail for surgery.

Contrast Reduction in TAVR CT Planning (European Radiology)

Layer et al. demonstrate that photon-counting detector CT (PCDCT) with 50 mL contrast (vs standard 80 mL) maintains diagnostic quality for TAVR planning when low-keV virtual monoenergetic reconstructions are used. In 162 BMI-matched examinations, the reduced-dose protocol with 50-keV VMI actually improved signal-to-noise and contrast-to-noise ratios compared to standard-dose polyenergetic imaging. A practical advance for the many CKD patients undergoing pre-TAVR CT.

TAVR Infective Endocarditis: Long-Term Suppressive Antibiotics (American Journal of Cardiology)

Kandil et al. report from Mayo Clinic on outcomes of long-term suppressive antimicrobial therapy in TAVR infective endocarditis. No abstract is available, but this addresses a growing clinical challenge: TAVR endocarditis carries high mortality and limited surgical options (THV explantation mortality 12–17%). As TAVR volumes grow and the implant population ages, understanding whether chronic suppressive antibiotics can serve as an alternative to high-risk explantation is clinically urgent.

Iron Deficiency and Myocardial Work After TAVI (Cardiology Journal)

Błaszkiewicz et al. report in a prospective study of 100 severe AS patients that iron deficiency (defined by TSAT <20%) was associated with absent improvement in LV myocardial work indices after TAVI at one year, whereas non-iron-deficient patients showed significant changes. An intriguing signal that iron status may modulate reverse remodeling after valve intervention, though the small sample and single-center design demand cautious interpretation.

Mitral Valve (MitraClip, PASCAL, TMVR)

AATS Consensus Document: Management of Atrial Functional Mitral Regurgitation (JTCVS)

[NOTABLE] Mori, Ailawadi, Bolling, Hahn, Kaneko, and an international multidisciplinary panel publish the 2026 AATS Expert Consensus on AFMR — 18 graded recommendations spanning five domains: (1) definition and diagnosis, (2) medical/rhythm therapy, (3) surgical treatment, (4) transcatheter/hybrid interventions, and (5) postoperative management. This is the first major surgical-society consensus specifically addressing AFMR as a distinct entity.

Editorial perspective: This document arrives at an important moment. The ESC 2025 guidelines formally recognized atrial secondary MR — MR driven by LA dilation and annular remodeling in patients with preserved LVEF, typically in the context of AF — but provided relatively limited management detail. The ACC/AHA 2020 guidelines barely mentioned this phenotype. The AATS consensus fills the gap with actionable guidance, reportedly addressing when to offer surgery (MV repair + AF ablation + LAAO), when TEER is appropriate, and how to manage rhythm postoperatively. The emphasis on integrated rhythm management is particularly welcome — isolated valve intervention without addressing AF is unlikely to produce durable results in this population. This should be required reading for every Heart Team.

MITRACURE Registry: Real-World Surgical Outcomes in Degenerative MR (JTCVS)

[NOTABLE] Bouchard, Dreyfus, and colleagues present the MITRACURE registry — 2,135 patients with degenerative MR across 40 centers in Canada and France. The headline numbers: 80% repair rate, 2.3% in-hospital mortality (1.4% for repair, 6.2% for replacement), and 20% major complication rate. But the deeper story is concerning: only 17% were truly asymptomatic at surgery, only 4% received early intervention, and 37% were NYHA III/IV at presentation.

Editorial perspective: This is real-world data from two publicly funded healthcare systems — and it reveals the persistent gap between guideline recommendations and clinical practice. The ESC 2025 guidelines upgraded early repair in asymptomatic patients with risk factors to Class I, and the ACC/AHA 2020 called it Class IIa. Yet early intervention was performed in only 4% of this cohort. The volume-outcome relationship is equally striking: high-volume centers achieved 84% repair rates vs 68% at low-volume centers — a 16-point gap that directly translates to mortality differences (1.4% repair vs 6.2% replacement). These data support surgical centralization and earlier referral pathways, and they provide the benchmark against which transcatheter mitral approaches must be judged.

CT Fatty Muscle Fraction: A New Frailty Marker for M-TEER (Circ: Cardiovascular Imaging)

Salam et al. report that CT-derived fatty muscle fraction (FMF) at the L3 vertebral level, measured from routine pre-procedural CT using deep learning segmentation, independently predicted mortality after M-TEER in 197 patients (median age 79, median EuroScore II 4.1). Patients in the highest FMF tertile (>56.69%) had 30.3% one-year mortality versus 7.7% in the lowest tertile — a four-fold difference. On multivariable analysis, FMF remained independently associated with mortality (HR 1.05 per percentage point, P<0.001).

Clinical note: This is a single-center retrospective study, and the FMF measurement requires validation in larger, multicenter cohorts. But the concept is appealing: every M-TEER patient already gets a CT, and automated body composition analysis adds negligible time. If validated, FMF could improve patient selection by identifying those too frail to benefit — a critical need given that the ESC 2025 guidelines now give TEER a Class I recommendation for ventricular SMR, which will inevitably expand the candidate pool.

Atrial Fibrillation and M-TEER Outcomes by MR Etiology (JACC: Asia)

Tanaka et al. analyze 3,764 M-TEER patients stratified by MR etiology and AF status. AF was prevalent across all groups but had strikingly different prognostic implications: it was associated with higher 2-year mortality in degenerative MR (adjusted HR 1.88, P=0.009) but not in ventricular functional MR or atrial functional MR. In VFMR, the AF-mortality association was modified by LA volume index — attenuated in patients with larger atria.

Editorial perspective: This has practical implications for patient counseling and procedural planning. In DMR patients undergoing TEER (typically high-risk patients ineligible for surgery), concomitant AF represents a significant mortality driver that valve repair alone won't address. This aligns with the AATS AFMR consensus emphasis on integrated rhythm management. In VFMR, the attenuation of AF risk with larger LA volumes likely reflects that advanced LA remodeling is already "priced in" to the baseline risk profile.

Valve-in-Valve TMVR: Single-Center Chinese Experience (Front Cardiovasc Med)

Zhang et al. report a retrospective series of 33 patients who underwent valve-in-valve TMVR for degenerated bioprosthetic mitral valves (100% technical success, 26 transapical, 7 transseptal). One patient died from cerebral infarction at day 7. NYHA class, EQ-VAS scores, and 6-minute walk distance all improved significantly at follow-up.

Limitations: Small sample, single center, no control group, and the mix of transapical and transseptal approaches limits generalizability. However, as the population of patients with degenerating surgical bioprosthetic mitral valves grows, valve-in-valve TMVR is an increasingly important — if technically demanding — option. Long-term outcomes, particularly regarding LVOT obstruction risk and neo-valve durability, remain unknown.

Tricuspid Valve (TriClip, TTVR)

No new tricuspid-specific publications today, but the clinical trial updates section below includes important activity: the TRICURE US IDE Pivotal Study (NCT07528326) has been registered, planning to enroll 831 patients comparing the TRiCares Topaz TTVR system against Edwards EVOQUE. This head-to-head transcatheter tricuspid replacement trial represents the next frontier in TR therapy — device competition that could accelerate innovation and clarify optimal approaches. The Ottawa Heart Institute's functional TR outcomes registry (NCT05825898, 3,500 patients) is also actively enrolling by invitation, promising crucial comparative data between medical, transcatheter, and surgical management strategies.

Surgical vs. Transcatheter Comparisons

The Badhwar/Mehaffey Editorial in Context

The Wolfe, Mehaffey, and Badhwar editorial "Convenience Now, Complexity Later" arrives at the AATS meeting as a deliberate counterpoint to the transcatheter momentum reflected in the ESC 2025 guidelines and recent meta-analyses. It's worth framing this within the broader evidence landscape:

For TAVR in younger patients: The DEDICATE trial showed TAVI non-inferiority with numerically better outcomes at 1 year in lower-risk patients. The updated meta-analysis (JACC, 2026) showed HR 0.80 for death at 5 years favoring TAVR. The ESC lowered the TAVI-preferred threshold to age ≥70 with tricuspid AV and suitable anatomy.
Against TAVR in younger patients: No RCT has >10 years of follow-up. Patients <70 are poorly represented in trials. THV explantation mortality is 12–17%. Reinterventions are rare but increasing (1.7% at 8 years, 84% redo-TAVR). Bicuspid valves — common in younger patients — show numerically worse outcomes with TAVI. Long-term data on mechanical vs. biological prostheses in patients aged 50–70 favor mechanical surgical valves for survival. Lifetime management planning (coronary access, valve-in-valve feasibility, PPM) is inadequately addressed at the index TAVI procedure.
The ACC/AHA 2020 vs ESC 2025 gap: The ACC/AHA prefers SAVR below age 65; the ESC prefers SAVR below 70. For ages 65–70, a patient sits in the ACC/AHA "shared decision" zone but the ESC "SAVR-preferred" zone — an unusual alignment where the European guidelines are actually more conservative than the American ones for this narrow age band.

Bottom line: neither camp has definitive evidence. The responsible position — and the one this newsletter takes — is that patients under 65 should generally receive SAVR unless surgical risk is elevated, patients over 80 should generally receive TAVI, and the 65–80 corridor requires genuine Heart Team deliberation that accounts for anatomy, comorbidities, bicuspid valve status, and lifetime management planning.

Preprint Highlights

Flow-Gradient Phenotypes and TAVI Recovery (medRxiv — COMPARE-TAVI 1 Sub-study)

Ravn et al. present a sub-study of 975 patients from the COMPARE-TAVI 1 trial, classifying patients by flow-gradient phenotype and tracking functional recovery at 1 year. The key finding: while all phenotypes improved after transfemoral TAVI, paradoxical low-flow low-gradient (pLFLG) patients showed significantly attenuated benefits — less improvement in 6-minute walk distance (-28±15 meters vs baseline comparison), more persistent symptoms (38.7% NYHA ≥II at 1 year), and blunted reverse remodeling. No differences in mortality or MACE were observed.

Clinical implication: This adds to the growing evidence that pLFLG AS — which the separate review by Armonis et al. addresses diagnostically — may represent a phenotype with intrinsic myocardial limitations that persist despite afterload reduction. While TAVI still provides benefit, patients and clinicians should have tempered expectations. This also raises the question of whether these patients might benefit from adjunctive therapies (HFpEF treatments, cardiac rehabilitation) after TAVI. Not yet peer-reviewed.

Device & Technology

Edwards Lifesciences: RESILIA Tissue Durability Data

According to Cardiovascular Business, Edwards Lifesciences' RESILIA tissue platform — used in both surgical and transcatheter bioprosthetic valves — has been associated with long-term durability data. RESILIA uses an integrity preservation process that eliminates residual aldehyde groups and employs a glycerolization storage method that avoids fixation with glutaraldehyde alone. This is relevant to the durability debate at the center of the TAVR-vs-SAVR discussion: if next-generation tissue processing can extend bioprosthetic valve life beyond current benchmarks, the calculus for younger patients shifts. However, "associated with durability" claims require scrutiny — we need to see the actual SVD rates, follow-up duration, and comparison methodology.

Hydra THV: Spanish Registry Launched

A new prospective registry (NCT07566624) for the Hydra transcatheter heart valve has been registered in Spain, planning to enroll 100 patients. The Hydra is a repositionable and retrievable self-expanding THV designed for challenging anatomies. While this is an early-stage registry without a comparator arm, it reflects the continued proliferation of TAVR platforms — which may eventually provide more tailored solutions for specific anatomies (bicuspid, small annulus, horizontal aorta) that current devices handle suboptimally.

Regulatory & Policy

No new regulatory updates today. However, the AATS meeting typically generates consensus statements and position papers that influence future guideline development — the AFMR consensus document published today is a prime example. Watch for additional AATS statements on concomitant procedures, surgical training standards, and quality metrics that may shape CMS coverage decisions and professional society positions.

Industry & Market

Edwards Lifesciences Q1 2026: TAVR and TMTT Growth

Stock Titan reports that Edwards Lifesciences lifted Q1 2026 sales on growth in both TAVR and TMTT (Transcatheter Mitral and Tricuspid Therapies) segments. This is consistent with the secular growth trajectory: TAVR volumes continue to expand (driven partly by the ESC 2025 guideline shift to age ≥70 and the EARLY TAVR expansion into asymptomatic patients), while TMTT is growing from a smaller base as PASCAL and EVOQUE gain traction. The critical question is whether TMTT can achieve the scale and margins to offset the inevitable TAVR growth deceleration as penetration matures.

Global Heart Valve Trial Momentum

Kalkine Media reports on accelerating global heart valve trial activity with US cases beginning — reflecting the broadening geographic reach of structural heart clinical research and the increasing number of competing transcatheter platforms entering pivotal evaluations.

Financial Analysis

The structural heart device sector shows a bifurcated picture today. Edwards Lifesciences remains the bellwether, reporting Q1 2026 growth across both TAVR and TMTT segments and attracting continued institutional buying (QRG Capital acquired 18,172 shares). However, the broader valuation question looms large: with a trailing P/E of 45.0 and forward P/E of 24.7, Edwards is priced for growth execution. The RESILIA durability data and TMTT pipeline (PASCAL, EVOQUE) provide the narrative, but investors are also watching for any deceleration in TAVR procedural volumes as the low-hanging fruit of high-risk and intermediate-risk patients becomes fully harvested.

The broader medtech universe is under significant pressure. Abbott has shed nearly 31% over six months and Medtronic almost 15%, reflecting macro headwinds (tariff concerns, FX pressures, Medicare reimbursement uncertainty) more than company-specific structural heart issues. Boston Scientific's 44% six-month decline is particularly severe, though the company's structural heart exposure (ACURATE neo2, WATCHMAN) represents a smaller revenue share than its electrophysiology and interventional cardiology businesses. For investors, the question is whether structural heart represents a defensive growth pocket within medtech or whether it too will be compressed by the same valuation pressures affecting the broader sector.

The private company landscape remains active: JenaValve (aortic regurgitation TAVR), J Valve Technology (now affiliated with Edwards, transfemoral pivotal study recruiting), and Meril Life Sciences (Myval, LANDMARK trial data showing non-inferiority) are all advancing programs that could reshape competitive dynamics. The registration of the TRICURE US IDE study (TRiCares Topaz vs EVOQUE for TTVR) signals that the transcatheter tricuspid replacement space is entering the head-to-head competition phase.

Valve Industry Stocks

6-Month Valve Industry Stock Performance

Edwards Lifesciences (EW)

Close: $83.20 (+$0.29, +0.35%)
6-Month Performance: -0.23% (essentially flat)
Market Cap: $48.0B | P/E (trailing): 44.97 | P/E (forward): 24.74
Beta: 0.87 | 52-Week Range: $72.30 – $87.89
Analyst Consensus: Buy | Target: $97.15 (range $84–$110, 27 analysts) — 16.8% upside
Next Earnings: July 23, 2026 (EPS est: $0.74, Rev est: $1.70B)
Volume: 5.1M shares

Edwards has been the relative outperformer among large-cap medtech in structural heart, essentially flat over six months while peers have declined sharply. Q1 2026 revenue growth across TAVR and TMTT supports the premium valuation, and RESILIA durability data provides a positive narrative. Institutional buying continues (QRG Capital). The stock is trading in the upper portion of its 52-week range, approaching a potential breakout above $88. However, the trailing P/E of ~45x requires consistent execution, and any softening in TAVR volumes or TMTT adoption would compress the multiple quickly. The AATS meeting backdrop — with surgical voices like Badhwar arguing against TAVR expansion — is worth monitoring for sentiment effects, though unlikely to change near-term procedure volumes.

Medtronic (MDT)

Close: $77.60 (-$0.19, -0.24%)
6-Month Performance: -14.52%
Market Cap: $99.6B | P/E (trailing): 21.68 | P/E (forward): 12.81
Beta: 0.63 | 52-Week Range: $77.16 – $106.33
Analyst Consensus: Buy | Target: $108.00 (range $90–$121, 25 analysts) — 39.2% upside
Next Earnings: June 3, 2026 (EPS est: $1.55, Rev est: $9.62B)
Volume: 11.5M shares

Medtronic is trading at its 52-week low ($77.16 was hit this week), representing a significant discount to intrinsic value per analyst estimates. The Evolut platform continues to hold significant TAVR market share, and the low-risk bicuspid study (NCT03635424) remains active. The Intrepid TMVR program is recruiting for its pivotal trial (1,056 patients). The forward P/E of 12.8x is extraordinarily cheap for a medtech large-cap, suggesting the market is pricing in broader concerns beyond structural heart — including Medtronic's diabetes and spine segments. Earnings on June 3 will be the next catalyst; any positive structural heart commentary could help stabilize the stock. However, the 14.5% six-month decline suggests institutional de-risking that may take time to reverse.

Abbott (ABT)

Close: $86.30 (-$0.87, -1.00%)
6-Month Performance: -30.93%
Market Cap: $150.3B | P/E (trailing): 24.17 | P/E (forward): 14.23
Beta: 0.65 | 52-Week Range: $86.15 – $139.06
Analyst Consensus: Buy | Target: $118.64 (range $92–$143, 25 analysts) — 37.5% upside
Next Earnings: July 16, 2026 (EPS est: $1.28, Rev est: $12.53B)
Volume: 12.5M shares

Abbott is at the bottom of its 52-week range after a brutal 31% six-month decline. In structural heart, the MitraClip/TriClip franchise is strategically important: the ESC 2025 upgrade of TEER for ventricular SMR to Class I (driven by COAPT 5-year data and RESHAPE-HF2) should expand MitraClip volumes, and TRILUMINATE data supports TriClip for TR. The REPAIR-MR trial (MitraClip vs surgery for primary MR) is active but not recruiting, and PRIMATY is enrolling. The disconnect between Abbott's structural heart clinical momentum and the stock's decline likely reflects litigation headwinds, nutritional segment pressures, and broad medtech multiple compression rather than structural heart fundamentals. For structural-heart-focused investors, the forward P/E of 14.2x at a 52-week low may represent an entry point — but macro risks persist.

Boston Scientific (BSX)

Close: $56.00 (+$0.02, +0.04%)
6-Month Performance: -44.01%
Market Cap: $83.2B | P/E (trailing): 23.43 | P/E (forward): 14.88
Beta: 0.62 | 52-Week Range: $54.98 – $109.50
Analyst Consensus: Strong Buy | Target: $85.19 (range $60–$110, 32 analysts) — 52.1% upside
Next Earnings: July 29, 2026 (EPS est: $0.83, Rev est: $5.40B)
Volume: 18.7M shares

Boston Scientific has experienced the steepest decline in the group — nearly halved in six months, now trading near $55 against a 52-week high of $109.50. The ACURATE neo2 IDE trial (NCT03735667, 1,948 patients) is active and not recruiting, representing BSX's primary TAVR competitive entry against SAPIEN and Evolut. The WATCHMAN LAAO franchise is relevant for AF-related valve disease patients. Despite the "Strong Buy" consensus (the most bullish rating in the group), the stock decline reflects macro pressures and potentially concerns about the ACURATE competitive position. The forward P/E of 14.9x is historically cheap for BSX. High-volume trading (18.7M shares) suggests significant institutional repositioning.

Anteris Technologies (AVR.AX)

Close: A$8.17 (-A$0.62, -7.05%)
6-Month Performance: +31.77%
Market Cap: A$0.8B | P/E (forward): -3.75 (pre-revenue)
Beta: 0.59 | 52-Week Range: A$4.68 – A$9.79
Analyst Target: A$13.00 (1 analyst)
DurAVR EU-EFS: NCT06510855 — active, not recruiting (40 patients)

Anteris stands out as the only stock in the group with positive 6-month returns (+31.8%), though today's 7% drop illustrates the volatility inherent in pre-revenue med-tech. The DurAVR single-piece TAVR valve — which uses a 3D-printed frame and ADAPT tissue — represents a differentiated approach to the durability challenge. The EU early feasibility study is active with 40 patients enrolled. With only one analyst covering the stock and a market cap under A$1B, Anteris remains a speculative play on next-generation TAVR technology rather than an investable structural heart position for most portfolios.

Private Companies

JenaValve Technology: Private. Developing the Trilogy TAVR system — notable for treating both aortic stenosis and native aortic regurgitation (the latter being Class IIb in ESC 2025 guidelines, representing an underserved market).
J Valve Technology: Private, now affiliated with Edwards Lifesciences. The J-Valve Transfemoral Pivotal Study (NCT06455787) is actively recruiting 194 patients.
Meril Life Sciences: Private. The Myval balloon-expandable THV demonstrated non-inferiority to SAPIEN and Evolut in the LANDMARK trial at 1 year (87.0% vs 86.9% freedom from death/stroke/valve hospitalization), establishing a competitive third option in the balloon-expandable TAVR space.

Market Outlook: The structural heart device sector faces a paradox: the clinical evidence base has never been stronger (ESC 2025 expanded indications across aortic, mitral, and tricuspid valves), but stock prices reflect macro-level medtech de-risking rather than procedure volume growth. The divergence between Edwards (flat) and Abbott/BSX/Medtronic (down 15–44%) partly reflects Edwards' pure-play structural heart positioning versus the diversified companies' exposure to non-cardiac headwinds. As AATS meeting data flows and Q2 earnings approach, watch for any signal that expanded TAVR indications (asymptomatic AS, age ≥70 threshold) are translating into measurable procedure volume acceleration — this would be the catalyst to re-rate the sector.

Clinical Trial Updates

Aortic Valve Trials

[LANDMARK] Evolut Low Risk Long-Term Follow-up (NCT02701283) — Status: Active, not recruiting | Enrollment: 2,223 | Sponsor: Medtronic | This is one of two pivotal low-risk TAVR trials (alongside PARTNER 3) that established TAVR non-inferiority in low-risk patients. Long-term follow-up beyond 5 years is critical for the durability debate and directly informs the SAVR-vs-TAVI age threshold discussion. Updated: 2026-03-19.
Medtronic TAVR Low Risk Bicuspid Study (NCT03635424) — Status: Active, not recruiting | Enrollment: 150 | Sponsor: Medtronic | Addresses a critical evidence gap: bicuspid aortic valve patients were excluded from RCTs and BAV TAVR remains Class IIb in both guidelines. Updated: 2026-05-05.
ACURATE IDE (NCT03735667) — Status: Active, not recruiting | Enrollment: 1,948 | Sponsor: Boston Scientific | Comparing ACURATE neo2 against both Medtronic and Edwards TAVR systems — the largest three-arm TAVR comparison. Updated: 2026-05-04.
DurAVR EU-EFS (NCT06510855) — Status: Active, not recruiting | Enrollment: 40 | Sponsor: Anteris Technologies | Early feasibility for the single-piece 3D-printed TAVR valve. Updated: 2026-05-04.
J-Valve Transfemoral Pivotal Study (NCT06455787) — Status: Recruiting | Enrollment: 194 | Sponsor: JC Medical/Edwards Lifesciences | Targeting both AS and native AR. Updated: 2026-05-04.
Hydra THV Spanish Prospective Registry (NCT07566624) — Status: Not yet recruiting | Enrollment: 100 | Sponsor: Fundación EPIC | New registry for an emerging TAVR platform. Updated: 2026-05-05.
Conscious Sedation for TAVI (NCT05462938) — Status: Completed | Enrollment: 65 | Sponsor: University of Ioannina | Propofol vs dexmedetomidine comparison. Updated: 2026-05-06.
Dexmedetomidine for TAVI (NCT07532733) — Status: Recruiting | Enrollment: 80 | Sponsor: Erasme University Hospital | Complementary to the dexmedetomidine safety data published today. Updated: 2026-04-30.
Impact of TAVI on Gut Microbiota (NCT07565077) — Status: Active, not recruiting | Enrollment: 40 | Sponsor: Insel Gruppe/University Hospital Bern | Exploratory. Updated: 2026-05-04.
NHLBI-Emory Advanced Cardiac CT Reconstruction (NCT05372627) — Status: Not yet recruiting | Enrollment: 1,000 | Sponsor: NHLBI | Advanced CT imaging for structural heart planning. Updated: 2026-05-06.

Mitral Valve — Repair Trials

[LANDMARK] REPAIR-MR (MitraClip vs Surgery for Primary MR) (NCT04198870) — Status: Active, not recruiting | Enrollment: 500 | Sponsor: Abbott | The first RCT directly comparing M-TEER to surgical repair for primary MR — critically important given that both ACC/AHA and ESC guidelines currently position TEER as subordinate to surgery for PMR. Results will reshape the treatment algorithm. Updated: 2025-11-12.
[LANDMARK] PRIMATY (MitraClip vs Medical Therapy for Secondary MR) (NCT05051033) — Status: Recruiting | Enrollment: 450 | Sponsor: Annetine Gelijns (NHLBI-funded) | Investigator-initiated comparison of TEER vs surgery for secondary MR — filling the gap between COAPT and real-world practice. Updated: 2026-03-03.
[LANDMARK] COAPT Long-Term Follow-up (NCT03706833) — Status: Active, not recruiting | Enrollment: 1,247 | Sponsor: Edwards Lifesciences | Now includes both PASCAL and MitraClip arms. Extended follow-up from the trial that drove the ESC 2025 upgrade of TEER for ventricular SMR to Class I. Updated: 2026-04-09.
M-TEER for Inotrope-Dependent Cardiogenic Shock (NCT05298124) — Status: Recruiting | Enrollment: 144 | Sponsor: Ottawa Heart Institute | Testing TEER in the sickest patients — cardiogenic shock. High-risk but potentially high-impact if positive. Updated: 2026-05-06.
MitraClip G5 Registry (NCT07543874) — Status: Not yet recruiting | Enrollment: 1,000 | Sponsor: University Hospital of Cologne | Post-market registry for the latest-generation MitraClip. Updated: 2026-05-01.
WATCH-TMVR (Watchman + MitraClip) (NCT04494347) — Status: Completed | Enrollment: 25 | Sponsor: Mayo Clinic | Combined LAAO + TEER approach for AF patients with MR. Updated: 2026-05-01.

Mitral Valve — Replacement Trials

Medtronic Intrepid TMVR (NCT03242642) — Status: Recruiting | Enrollment: 1,056 | Sponsor: Medtronic | The largest active TMVR pivotal trial. If positive, would establish a transcatheter replacement alternative for patients not candidates for repair. Updated: 2026-05-05.

Tricuspid Valve — Repair Trials

[LANDMARK] TRILUMINATE Pivotal (TriClip for TR) (NCT03904147) — Status: Active, not recruiting | Enrollment: 572 | Sponsor: Abbott | The pivotal trial that, along with Tri.Fr, drove the ESC 2025 Class IIa recommendation for transcatheter TR therapy. Long-term follow-up continues. Updated: 2024-12-19.
[LANDMARK] CLASP II TR (PASCAL for TR) (NCT04097145) — Status: Recruiting | Enrollment: 870 | Sponsor: Edwards Lifesciences | Edwards' PASCAL TEER system for TR, competing with Abbott's TriClip. Still actively recruiting. Updated: 2026-04-06.

Tricuspid Valve — Replacement Trials

[LANDMARK] TRISCEND II (EVOQUE Tricuspid Replacement) (NCT04482062) — Status: Active, not recruiting | Enrollment: 864 | Sponsor: Edwards Lifesciences | EVOQUE showed superiority for symptoms/QoL over medical therapy, with 98.4% TR reduction in real-world TVT Registry data. New pacemaker (15.9%) and bleeding (7.9%) rates remain concerns. Updated: 2026-02-27.
TRICURE US IDE Pivotal (Topaz vs EVOQUE) (NCT07528326) — Status: Not yet recruiting | Enrollment: 831 | Sponsor: TRiCares | Notable: The first head-to-head TTVR comparison trial. If TRiCares' Topaz system can demonstrate comparable efficacy with a different safety profile, it would validate TTVR as a device class rather than a single-device story. Updated: 2026-05-05.
Functional TR Outcomes Registry (NCT05825898) — Status: Enrolling by invitation | Enrollment: 3,500 | Sponsor: Ottawa Heart Institute | Comprehensive comparison of medical, transcatheter, and surgical treatment for functional TR. Updated: 2026-05-06.

Diagnostics

VoqX Computerized Stethoscope (NCT04960280) — Status: Completed | Enrollment: 400 | Sponsor: Mayo Clinic | AI-enabled auscultation for valve disease detection. Updated: 2026-05-05.

Social & Conference Highlights

AATS Annual Meeting (May 3–7, 2026) enters its final days. Today's highlights include the AFMR consensus document release and the MITRACURE registry data — both clearly timed for maximum impact at the surgical society's flagship meeting. The Badhwar/Mehaffey/Wolfe editorial in the Annals of Thoracic Surgery adds to the surgical perspective on TAVR expansion that permeates the AATS program. Cardiovascular Business has been running daily TAVR coverage focused on TAVR-vs-SAVR decision-making and long-term outcome prediction — themes that dominated today's literature as well.

Worth watching tomorrow: any late-breaking presentations from the final AATS sessions, particularly on concomitant surgical AF ablation (highlighted by a comprehensive review published today in the perioperative management space), bicuspid aortic valve management, and tricuspid surgery quality metrics.

Looking Ahead: As the AATS meeting closes, the field enters a bridge period before the next major meeting cycle. Key near-term catalysts include Medtronic earnings (June 3) with structural heart commentary, Abbott and Edwards earnings in July, and the ongoing enrollment of PRIMATY, CLASP II TR, and Intrepid TMVR. The AFMR consensus document and the JAMA Cardiology sex-disparity data both demand Heart Team action — not just academic acknowledgment. Tomorrow's digest will capture any final AATS late-breakers.

— E. Nolan Beckett, The Valve Wire

← May 6, 2026